Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $130.00 | Overweight | Morgan Stanley |
| 9/25/2025 | $75.00 | Peer Perform → Outperform | Wolfe Research |
| 9/22/2025 | $72.00 | Overweight | Wells Fargo |
| 4/10/2025 | $55.00 | Outperform | Mizuho |
| 1/23/2025 | $60.00 | Overweight | Barclays |
| 6/28/2024 | $36.00 | Neutral → Buy | Guggenheim |
| 6/3/2024 | $32.00 | Buy | Jefferies |
| 4/24/2024 | $28.00 | Buy | Craig Hallum |
Leading European Hospital System Begins Offering On-site Liquid Biopsy Testing Based on Proprietary Guardant360® CDx Technology Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer o
Presentations highlight advancements in cancer recurrence detection with Guardant Reveal and real-time treatment response monitoring with Guardant360 Liquid Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD) and Guardant360 Liquid, the company's comprehensive multiomic profiling te
34-member consortium creates an interoperable data standard for AI and distributed analytics Notable founding members include Guardant Health, NetApp, Seagate, IBM, DDN, and Genentech Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often disruptive, time-consuming, and ultimately costly due to progressively larger data sets needing faster solutions. SNS addresses this critical need by accelerating
144 - Guardant Health, Inc. (0001576280) (Subject)
8-K - Guardant Health, Inc. (0001576280) (Filer)
424B5 - Guardant Health, Inc. (0001576280) (Filer)
Morgan Stanley resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $130.00
Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00
Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C
For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap
For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry
4 - Guardant Health, Inc. (0001576280) (Issuer)
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th
Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release
Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look
Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%, driven by: Oncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40% Screeni
Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)